Alzheimer’s, three FDA advisers resign after approval of the drug aducanumab

“THIS could be the worst decision the FDA has made and I can remember”, with these words Aaron Kesselheim, a lecturer at Harvard Medical School and Brigham and Women’s Hospital, resigned after six years on the Food and Drug Administration’s advisory board. At the center of the controversy, the approval of the controversial Alzheimer’s drug by Biogen – aportanumab, marketed as Aduhelm – instead welcomed by a part of the scientific world as a “breakthrough” for the treatment of the disease that affects millions of people in the world (there were 47 million in 2018).